0001534122-14-000073.txt : 20141201 0001534122-14-000073.hdr.sgml : 20141201 20141201133333 ACCESSION NUMBER: 0001534122-14-000073 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20141125 FILED AS OF DATE: 20141201 DATE AS OF CHANGE: 20141201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cell MedX Corp. CENTRAL INDEX KEY: 0001493712 STANDARD INDUSTRIAL CLASSIFICATION: METAL MINING [1000] IRS NUMBER: 383939625 FISCAL YEAR END: 0930 BUSINESS ADDRESS: STREET 1: 4575 DEAN MARTIN DRIVE, SUITE 2206 CITY: LAS VEGAS STATE: NV ZIP: 89103 BUSINESS PHONE: (310) 508-9398 MAIL ADDRESS: STREET 1: 4575 DEAN MARTIN DRIVE, SUITE 2206 CITY: LAS VEGAS STATE: NV ZIP: 89103 FORMER COMPANY: FORMER CONFORMED NAME: Sports Asylum, Inc. DATE OF NAME CHANGE: 20140324 FORMER COMPANY: FORMER CONFORMED NAME: Plandel Resources, Inc. DATE OF NAME CHANGE: 20100608 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ARNETT JEAN M CENTRAL INDEX KEY: 0001626660 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-54500 FILM NUMBER: 141257260 MAIL ADDRESS: STREET 1: 121 - 3989 HENNING DRIVE CITY: BURNABY STATE: A1 ZIP: V5C 6P8 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2014-11-25 0 0001493712 Cell MedX Corp. CMXC 0001626660 ARNETT JEAN M 121 - 3989 HENNING DRIVE BURNABY A1 V5C 6P8 BRITISH COLUMBIA, CANADA 1 1 1 0 VP, Corporate Strategy Stock Options (Right to Buy) 0.05 2014-11-25 4 A 0 1250000 0 A Common Stock 1250000 1250000 D Stock Options (Right to Buy) 0.05 2014-11-25 4 A 0 1250000 0 A Common Stock 1250000 1250000 D Stock Options (Right to Buy) 0.05 2014-11-25 4 A 0 1250000 0 A Common Stock 1250000 1250000 D Stock Options (Right to Buy) 0.05 2014-11-25 4 A 0 1250000 0 A Common Stock 1250000 1250000 D Stock Options (Right to Buy) 0.05 2014-11-25 4 A 0 2500000 0 A Common Stock 2500000 2500000 D Stock Options (Right to Buy) 0.05 2014-11-25 4 A 0 2500000 0 A Common Stock 2500000 2500000 D The Options will vest upon the design and commencement of first clinical trials. The Options will vest upon the completion of first clinical trials and delivery of final white paper for first clinical trials. The Options will vest upon the design and commencement of second clinical trials. The Options will vest upon the completion of second clinical trials and delivery of final white paper for second clinical trials. The Options will vest upon the design and commencement of third clinical trials The Options will vest upon the completion of the third clinical trials and delivery of final white paper for third clinical trials. Options that have vested will expire 5 years after vesting. Options that have not vested will expire on 12/31/2019. The filing of this statement shall not be deemed an admission that the Reporting Person is the beneficial owner of any of the equity securities listed in this statement for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Jean M. Arnett 2014-11-25